Q3 2026 results reflect:
Growth Outperforming Markets
- +4.0% Worldwide sales led by +8.6% U.S. dental merchandise sales
- +6.1% Specialty sales driven by growth in value & premium implants
- +5.2% Technology sales driven by net new customers and price
Unlocking Earnings Power
- +13.0% non-GAAP EPS and +19.1% adjusted non-GAAP EPS
- ~30 bps gross margin expansion** driving underlying earnings growth
- Stronger Q3 performance than expected thanks to outstanding execution, reinforces our confidence in delivering FY double-digit EPS growth
Raising FY Guidance
- Increasing FY2026 non-GAAP EPS to $5.53 at midpoint and Adj. EBITDA
- Reflecting improved underlying performance and the impact of net tariff refund benefits
- Investments in growth initiatives in Q4 to continue to drive share gains